Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074570 | 0.78 | DAO (0.42) | GABRA1GABRB2AKR1B1ADRA2BADRA2C | |
| SCHEMBL5691773 | 0.78 | HDAC8 (0.42) | GABRA1GABRB2AKR1B1ADRA2BADRA2C | |
| SCHEMBL173300 | 0.71 | GABRA1 (0.56) | GABRA1GABRB2AKR1B1ADRA2BADRA2C | |
| SCHEMBL29763626 | 0.71 | GABRA1 (0.56) | GABRA1GABRB2AKR1B1ADRA2BADRA2C | |
| SCHEMBL9319 | 0.71 | — | — | |
| SCHEMBL1531012 | 0.71 | GABRA1 (0.35) | GABRA1GABRB2 | |
| SCHEMBL27763265 | 0.70 | — | — | |
| Hydrogen Sulfide SCHEMBL29094904 | 0.70 | — | — | |
| Methane SCHEMBL27677204 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL27996106 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104093560-B | Thin-film laminate | 日本曹达株式会社 | 2016-10-26 | — | — | CN | disclosed |
| CN-104093560-A | Thin-film laminate | NIPPON SODA CO | 2014-10-08 | — | — | CN | disclosed |
| US-8084471-B2 | Proteomimetic compounds as inhibitors of the interaction of nuclear receptor with coactivator peptides | YALE UNIVERSITY (US) | 2011-12-27 | — | — | US | disclosed |
| CN-101087813-B | Method for removing metal and method for producing polymer | NIPPON SODA CO | 2010-05-12 | — | — | CN | disclosed |
| CN-100594184-C | Dispersion of titanium oxide particles, titanium oxide thin film, solution for forming organic functional film, substrate having organic functional film formed thereon and method for producing same | NIPPON SODA CO | 2010-03-17 | — | — | CN | disclosed |
| CN-100551944-C | Polymer solid electrolyte | NIPPON SODA CO (JP) | 2009-10-21 | — | — | CN | disclosed |
| US-20090220586-A1 | PROTEOMIMETIC COMPOUNDS AS INHIBITORS OF THE INTERACTION OF NUCLEAR RECEPTOR WITH COACTIVATOR PEPTIDES | YALE UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2008030408-A2 | PROTEOMIMETIC COMPOUNDS AS INHIBITORS OF THE INTERACTION OF A NUCLEAR RECEPTOR WITH COACTIVATOR PEPTIDES | YALE UNIVERSITY (US) | 2008-03-13 | — | — | WO | disclosed |
| CN-101115682-A | Dispersion of titanium oxide particles, titanium oxide thin film, solution for forming organic functional film, substrate having organic functional film formed thereon and method for producing same | NIPPON SODA CO (JP) | 2008-01-30 | — | — | CN | disclosed |
| CN-101087813-A | Method for removing metal and method for producing polymer | NIPPON SODA CO (JP) | 2007-12-12 | — | — | CN | disclosed |
| CN-1668662-A | Solid polymer electrolyte | NIPPON SODA CO (JP) | 2005-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220586-A1 | PROTEOMIMETIC COMPOUNDS AS INHIBITORS OF THE INTERACTION OF NUCLEAR RECEPTOR WITH COACTIVATOR PEPTIDES | NCOA1, NCOA2, NCOA3 | GABRA1 2177/4885GABRB2 1918/4885AKR1B1 2971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.